AbCellera Biologics

AbCellera Biologics

Biotechnology firm specializing in antibody therapies

About AbCellera Biologics

Simplify's Rating
Why AbCellera Biologics is rated
A-
Rated B on Competitive Edge
Rated A on Growth Potential
Rated A on Rating Differentiation

Industries

AI & Machine Learning

Biotechnology

Healthcare

Company Size

501-1,000

Company Stage

IPO

Headquarters

Vancouver, Canada

Founded

2012

Overview

AbCellera specializes in discovering and developing therapeutic antibodies for various diseases. The company uses a proprietary technology platform that combines different scientific methods to identify and create antibodies efficiently. Clients, including pharmaceutical companies and research institutions, partner with AbCellera to enhance their drug development processes. Unlike many competitors, AbCellera focuses on challenging targets that traditional methods struggle to address. The company's goal is to accelerate the development of new antibody therapies through collaboration and its own internal programs, generating revenue from partnerships, discovery services, and licensing agreements.

Simplify Jobs

Simplify's Take

What believers are saying

  • AbCellera's collaboration with Biogen targets the challenging blood-brain barrier in neuroscience.
  • Partnerships with Viking and ArrowMark aim to launch new biotech companies in immunology.
  • The growing trend of AI-driven discovery complements AbCellera's existing technology strengths.

What critics are saying

  • Increased competition from AI-integrated drug discovery firms may challenge AbCellera's market position.
  • Dependency on major partners like AbbVie and Eli Lilly could pose risks if relationships change.
  • Scientific challenges in crossing the blood-brain barrier may delay Biogen collaboration outcomes.

What makes AbCellera Biologics unique

  • AbCellera excels in rapid antibody discovery with its integrated technology platform.
  • The company has strong partnerships with leading pharmaceutical firms like AbbVie and Eli Lilly.
  • AbCellera's focus on T-cell engagers positions it at the forefront of oncology innovation.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$1194.3M

Above

Industry Average

Funded Over

5 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison
Coming Soon

Benefits

Paid Vacation

Paid Sick Leave

Flexible Work Hours

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

3%
Montreal Gazette
Mar 25th, 2025
AbCellera Announces Presentation of In Vivo Data on PSMA x CD3 T-Cell Engagers at AACR 2025

AbCellera announces presentation of in vivo data on PSMA x CD3 T-Cell engagers at AACR 2025.

Stock Titan
Jan 13th, 2025
AbCellera Expands Collaboration with AbbVie to Develop Novel T-Cell Engagers for Oncology

AbCellera (ABCL) has expanded its collaboration with AbbVie (ABBV) to develop novel T-cell engagers (TCE) in oncology, building upon their partnership from December 2022.

North Carolina Biotechnology Center
Sep 30th, 2024
Dualogics Sells Antibody Platform to Canadian Company | North Carolina Biotechnology Center

Durham-based Dualogics has sold its core technology for producing therapeutic antibodies to a Canadian biotechnology company.

Stock Titan
Jul 31st, 2024
AbCellera and Lilly Expand Collaboration to Develop Antibody Medicines

AbCellera (Nasdaq: ABCL) has expanded its collaboration with Eli Lilly to develop antibody medicines for immunology, cardiovascular disease, and neuroscience programs.

Securities.io
Jun 13th, 2024
Top 10 Biotech Big Data Companies

More Data For Better MedicineThe more we learn about biology, the more we realize all we do not know. It started with the genomic revolution and the first human genome sequenced in the early 2000s.Genomics has now been joined by other datasets like transcriptomics, proteomics, metabolomics, microbiome, etc. forming a new “multiomics” science. We discussed in further detail this evolution in “ Multiomics Are The Next Step In Biotechnology ”.These new tools have created a flood of data bringing detailed information about the inner activities of cells sometimes down to the atomic level. A key driver of this data growth has been the collapse of price of sequencing gene and other biological materials like proteins.This has created enthusiasm about “Big Data” potential in biotech, mimicking the concept of big data from other, more IT-driven fields.Already in 2018, the magazine Barron’s was asking “ Will Big Data Lead to Big Biotech Returns? ” and the industry started to ask “ Implementing Large-Scale Data Processing and Analysis for Bioprocessing ”Quite a few companies are well-positioned to benefit from the drive to create and analyze at-scale biological data.AI Merging With Big Data?A new development in the last few years has been the emergence of AI. While AI made its way into public consciousness mostly in 2023, with LLMs (Large Language Models) like ChatGPT, the biotech industry started to embrace AI many years before that.And it makes sense because data and AI have a somewhat symbiotic relationship:Training AI models requires a lot of data with high quality and annotations.AIs can help sort out massive datasets without direct human intervention and connect the dots where manual analysis would not be possible.The result is that today, a lot of the previously big data-focused companies in the biotech industry are also turning into AI companies.Contrary to some AI applications still looking for a business model (like image generation), drug discovery and medical research have a pretty straightforward path from AI model to monetization.Top 10 Big Data Biotech StocksIllumina is the leading genomics company, by far the largest and most established in the industry, with $1.2B in revenues, which grew 11% CAGR in the last 5 years.This also makes it the prime provider of genomic data to the entirety of the biotech industry.Like most genome sequencing companies, Illumina makes money when selling sequencers but mostly when selling the consumables used by the sequencers

Recently Posted Jobs

Sign up to get curated job recommendations

Scientifique principal - Pharmacocinétique & bioanalyse

Montreal, QC, Canada

Senior Clinical Study Manager

Montreal, QC, Canada

Utilities Systems Operator - Facilities and Engineering

CA$60.6k - CA$75.7k/yr

Vancouver, BC, Canada

See All Jobs

AbCellera Biologics is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update AbCellera Biologics's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to AbCellera Biologics

Arcellx

Arcellx

Gaithersburg, Maryland

Abata Therapeutics

Abata Therapeutics

Cambridge, Massachusetts

Cellares

Cellares

South San Francisco, California

Senior Clinical Study Manager

Montreal, QC, Canada

Utilities Systems Operator - Facilities and Engineering

CA$60.6k - CA$75.7k/yr

Vancouver, BC, Canada

See All Jobs

AbCellera Biologics is Hiring for 17 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update AbCellera Biologics's jobs every few hours, so check again soon! Browse all jobs →

People Also Viewed

Discover companies similar to AbCellera Biologics

Arcellx

Arcellx

Gaithersburg, Maryland

Abata Therapeutics

Abata Therapeutics

Cambridge, Massachusetts

Cellares

Cellares

South San Francisco, California